Whole Genome Sequencing for CBS/PSP

Parent page: Personalized Treatment Plan

3.4 Whole Genome Sequencing (WGS)

Rationale: While the targeted genetic panel (GBA, LRRK2, MAPT, C9orf72, PRKN, PINK1, VPS35) covers the most common genetic causes of atypical parkinsonism, whole genome sequencing provides comprehensive coverage of the entire genome, including:

Rare variants in known parkinsonism genes not included in panels
Non-coding regulatory variants affecting gene expression
Copy number variations (CNVs) and structural variants
Mitochondrial DNA variants
Novel gene discoveries not yet clinically validated

Recommended Strategy

Step	Test	When	Rationale
1	Targeted panel first	Initial workup	Cost-effective, faster turnaround, covers 80%+ of actionable variants
2	If panel negative	After panel results	WGS can identify rare variants, non-coding changes, structural variants

Short-Read WGS (Illumina)

Provider	Cost	Turnaround	Coverage	Key Features
GeneDx	$1,500-3,000	4-6 weeks	30x genome-wide	Includes deletion/duplication analysis, interpretative report
Invitae	$1,200-2,000	3-5 weeks	30x genome-wide	Hereditary parkinsonism panel included; WGS for complex cases
Mayo Clinic Labs	$2,000-3,500	6-8 weeks	30x genome-wide	Includes mitochondrial genome, CNV analysis
Fulgent Genetics	$1,000-2,000	3-4 weeks	30x genome-wide	Large gene panel, WGS option
Blueprint Genetics	$1,500-2,500	4-6 weeks	30x genome-wide	Focus on neurological disorders

Pros: Most cost-effective, well-validated pipelines, large database matching Cons: Struggles with repetitive regions, structural variants, large insertions

Long-Read WGS (PacBio/Nanopore)

Provider	Cost	Turnaround	Coverage	Key Features
GeneDx (Revio)	$3,000-5,000	6-8 weeks	30x HiFi reads	Highest accuracy for structural variants, repeat expansions
Pacific Biosciences	$3,500-6,000	8-12 weeks	Custom coverage	HiFi reads (99.9% accuracy), resolving complex regions
Oxford Nanopore	$2,500-4,500	4-8 weeks	Variable	Portable sequencer option, real-time analysis
Helix	$2,500-4,000	6-8 weeks	30x	Long-read analysis for repeat expansion disorders
Baylor Genetics	$3,000-5,000	6-10 weeks	30x	Comprehensive structural variant detection

Pros: Superior for structural variants, repeat expansions (e.g., GBA1, ATXN2), GC-rich regions, haplotype phasing Cons: Higher cost, fewer labs offer it, some platforms have higher error rates (though HiFi/PromethION are highly accurate)

Recommendation for This Patient

Priority: Moderate-high (given atypical presentation, negative alpha-synuclein SAA, and diagnostic uncertainty)

Start with targeted panel (GBA, LRRK2, MAPT, C9orf72, PRKN, PINK1, VPS35)
- Cost: ~$500-2,000
- Turnaround: 2-4 weeks
- Actionable results in ~10-15% of atypical parkinsonism cases
If panel negative, proceed to short-read WGS
- Cost: ~$1,500-2,500
- Turnaround: 4-6 weeks
- Expected to find additional pathogenic variants in ~5-10% of panel-negative cases
Consider long-read WGS if:
- Short-read WGS is negative but clinical suspicion remains high
- Family history of similar disorders (even if apparently sporadic)
- Suspicion of repeat expansion disorders (e.g., Huntington’s, SCA, FTD)
- Need for comprehensive structural variant analysis

Insurance Coverage

Medicare: Covers WGS for certain indications (developmental disorders, unexplained conditions); CBS/PSP may qualify
Commercial: Often requires pre-authorization; medical necessity documentation critical
Out-of-pocket: Most labs offer payment plans; some have financial assistance programs

Patient Action Items

Request genetic counseling referral before testing
Confirm insurance coverage and pre-authorization
Consider cascade testing for family members if pathogenic variant found
Discuss implications for family planning and at-risk relatives
Store DNA sample for future testing if needed

Genetic Architecture of CBS and PSP

flowchart TD
    PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
    PSP["PSP"] -->|"associated with"| Als["Als"]
    PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
    PSP["PSP"] -->|"expressed in"| neurons["neurons"]
    PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
    PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
    PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
    PSP["PSP"] -->|"regulates"| STX6["STX6"]
    PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
    PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
    PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
    PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
    PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
    PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
    style PSP fill:#4fc3f7,stroke:#333,color:#000

Understanding the genetic landscape of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) is essential for interpreting WGS results and counseling patients[“@singleton2024”][@blauwendraat2024].

Known Genetic Causes

Autosomal Dominant Genes

Gene	Inheritance	CBS Phenotype	PSP Phenotype	Frequency
MAPT	AD	~5-10%	~15-20%	Most common genetic cause of PSP
C9orf72	AD	~5%	~3%	Hexanucleotide repeat expansion
GRN	AD	~3-5%	~1-2%	Progranulin deficiency
TBK1	AD	~2%	~1%	Autophagy/innate immunity
VPS35	AD	~1-2%	Rare	Retromer dysfunction

Autosomal Recessive Genes

Gene	Inheritance	Associated Phenotype	Notes
PRKN	AR	Early-onset PD, CBS-like	Juvenile onset common
PINK1	AR	Early-onset PD	May present as CBS
DJ-1	AR	Early-onset PD	Rare
ATP13A2	AR	Kufor-Rakeb syndrome	Atypical parkinsonism

Variant Spectrum

The genetic architecture of CBS and PSP differs significantly from typical Parkinson’s disease[@kim2023]:

MAPT mutations: Primarily responsible for familial PSP and a subset of familial CBS. Haplotype H1 is a major risk factor for sporadic PSP.
Sporadic cases: Even without family history, WGS identifies pathogenic variants in 15-25% of clinically diagnosed CBS and 20-30% of PSP cases.
Phenotypic variability: The same mutation can produce different phenotypes within families, making prediction challenging.

Genetic Risk Factors

Beyond highly penetrant mutations, common variants influence disease risk:

MAPT H1 haplotype: Major risk factor for PSP, increasing risk 3-5x
STX6, MOBP, EGF: Other identified risk loci for PSP
GBA variants: Risk factor for PD and CBS, modifying disease severity

Technical Considerations for WGS

Sequencing Parameters

Parameter	Recommended	Rationale
Coverage	≥30x genome-wide	Ensures reliable variant calling
Read length	150 bp (paired-end)	Standard short-read format
Quality threshold	Q30+ per base	High accuracy for variant detection
Batch processing	Yes (when possible)	Reduces per-sample cost

Bioinformatics Pipeline

A robust WGS analysis pipeline includes:

Alignment: BWA-MEM2 or similar to reference genome (GRCh38)
Variant calling: GATK HaplotypeCaller or DeepVariant
Quality filtering: PASS thresholds, removal of low-quality calls
Annotation: VEP, SnpEff for functional prediction
Filtering: Population frequency, pathogenicity scores, gene lists

Coverage Considerations

Region	Typical Depth	Notes
Exomes	30-50x	Higher coverage in coding regions
Introns	20-30x	Sufficient for splice variants
Regulatory	15-25x	May require deeper coverage
Mitochondrial	100x+	Higher for homoplasmy detection
Repetitive	Variable	May have lower callability

Interpretation Challenges

Variant Classification

Interpreting WGS results requires careful variant classification[@orto2022]:

Classification	Criteria	Clinical Action
Pathogenic	Confirmed disease-causing	Report to patient, cascade testing
Likely pathogenic	Strong evidence, high suspicion	Report, consider confirmation
Variant of uncertain significance (VUS)	Insufficient evidence	Counsel, research follow-up
Likely benign	Strong evidence against pathogenicity	May not report
Benign	Evidence of no clinical significance	Do not report

VUS Management

VUS present a significant challenge in clinical interpretation:

Reclassification: Periodic re-evaluation as new evidence emerges
Functional studies: Research-based assessment when possible
Family segregation: Testing affected and unaffected relatives can help
Gene-specific resources: Check ClinGen, GeneDx, literature for updated guidance

Technical Limitations

Limitation	Impact	Mitigation
Repeat regions	Poor mapping, false negatives	Long-read WGS for repeat expansions
Structural variants	Difficult to detect	CNV analysis, read-depth methods
Mosaicism	May be missed	Higher coverage, mosaic-aware callers
Non-coding variants	Interpretation challenging	RegulomeDB, functional genomics

Clinical Utility of WGS

Diagnostic Yield

WGS provides significant diagnostic information in CBS and PSP[@chen2023][@poston2023]:

Population	Diagnostic Yield	Notes
Typical CBS	15-25%	Higher than PD
PSP with family history	30-40%	MAPT, GRN, C9orf72
Early-onset (<50)	25-35%	More likely monogenic
Sporadic PSP	15-20%	Mainly MAPT haplotypes
Atypical presentations	20-30%	Broader differential

Comparison with Targeted Panels

Targeted panels remain appropriate for initial testing[@singh2020]:

Feature	Targeted Panel	WGS
Genes covered	20-100	All genes
Cost	$500-2,000	$1,500-5,000
Turnaround	2-4 weeks	4-8 weeks
Non-coding variants	Limited	Comprehensive
Structural variants	Limited	Better detection
Novel gene discovery	No	Yes

WGS is recommended when:

Targeted panel is negative
Phenotype is atypical
Strong family history
Early-onset disease
Suspicion of rare genetic etiology

Family Testing Implications

Cascade Testing

When a pathogenic variant is identified, family members may benefit from testing[@patel2021]:

First-degree relatives: 50% chance of carrying variant (autosomal dominant)
At-risk relatives: Pre-symptomatic testing available
Reproductive counseling: Options for family planning
Penetrance considerations: Not all carriers develop disease

Ethical Considerations

Genetic testing raises important ethical issues:

Psychological impact: Anxiety, insurance concerns, family tension
Reproductive decisions: Informed choices about family planning
Insurance implications: GINA protections (US), state-specific laws
Incidental findings: Variants unrelated to indication
Testing children: Generally not recommended unless actionable

Pre-Test Counseling

Essential components before testing:

Discussion of possible results: Pathogenic, VUS, negative
Implications for family: Cascade testing considerations
Psychological preparation: Potential for uncertain findings
Insurance/financial: Coverage, out-of-pocket costs
Reproductive implications: Options, family planning

Research Applications

Gene Discovery

WGS enables identification of novel genetic causes:

Novel genes: Continue to be discovered through research WGS
Non-coding regulatory variants: Expression quantitative trait loci (eQTLs)
Polygenic risk: Aggregate effects of common variants
Epigenetic modifications: DNA methylation patterns

Biomarker Development

Genetic findings inform biomarker research:

Genetic stratification: Enrichment for clinical trials
Endophenotypes: Intermediate traits linked to genotypes
Predictive markers: Age of onset, progression rate
Treatment response: Pharmacogenomics

Therapeutic Targets

Genetic discoveries point to therapeutic pathways:

MAPT: Tau aggregation inhibitors, antisense oligonucleotides
GRN: Progranulin replacement therapy
C9orf72: Antisense therapy development
GBA: Enzyme enhancement, substrate reduction

Quality Assurance

Laboratory Standards

Standard	Description	Importance
CLIA certified	Clinical laboratory compliance	Results for medical decision-making
CAP accredited	College of American Pathologists	Quality assurance
ISO 15189	Medical laboratory quality	International standard
ACMGL guidelines	Variant interpretation	Consistent classification

Validation Requirements

Analytical validation: Accuracy, precision, reproducibility
Clinical validation: Sensitivity, specificity in known samples
Proficiency testing: External quality assessment
Internal controls: Sample quality, pipeline performance

Cost-Effectiveness

Healthcare Economics

WGS demonstrates favorable cost-effectiveness in certain scenarios[@robinson2022]:

Scenario	Cost-Effectiveness	Rationale
Early-onset atypical parkinsonism	Favorable	High diagnostic yield
Family history positive	Favorable	Likely monogenic
Negative panel → WGS	Variable	Depends on pre-test probability
Routine clinical	Unfavorable	Low yield in typical cases

Value Components

Beyond diagnostic utility, WGS provides value through:

Avoided testing: Reduced unnecessary workup
Informative planning: Family counseling, prognosis
Trial eligibility: Genetic stratification for trials
Research contribution: Advancing field knowledge

Implementation Recommendations

Clinical Workflow

Pre-test assessment: Confirm indication, genetic counseling
Test selection: Panel vs. WGS based on clinical context
Sample collection: Standard blood, appropriate tube
Laboratory processing: CLIA-certified, appropriate pipeline
Result interpretation: Multidisciplinary review
Post-test counseling: Results disclosure, family discussion

Sample Requirements

Parameter	Specification
Sample type	Peripheral blood (EDTA)
Volume	3-5 mL adults, 1-3 mL pediatric
DNA quantity	≥1 μg recommended
Quality	A260/A280 1.8-2.0
Turnaround	4-8 weeks typical

Specific Gene Considerations

MAPT (Microtubule-Associated Protein Tau)

MAPT mutations are the most common genetic cause of PSP[@blauwendraat2024]:

Inheritance: Autosomal dominant with incomplete penetrance
Mechanism: Mutations affect tau splicing, function, or aggregation
Key variants: P301L, P301S, IVS10+16, IVS10+3
Testing considerations: Haplotype analysis for H1 risk allele

Clinical implications:

Earlier age of onset (typically 50-70 years)
Family history in ~30% of cases
Potential response to tau-directed therapies

C9orf72 Hexanucleotide Repeat Expansion

The C9orf72 expansion is a major cause of frontotemporal dementia and ALS, with some patients presenting as CBS or PSP:

Normal: <30 repeats
Intermediate: 30-50 repeats (reduced penetrance)
Pathogenic: >50 repeats (high penetrance)

Testing considerations:

Requires specific repeat-primed PCR or Southern blot
May show reduced penetrance in some families
Anticipation (earlier onset in subsequent generations)

GRN (Progranulin)

GRN mutations cause progranulin deficiency, leading to TDP-43 pathology:

Inheritance: Autosomal dominant with haploinsufficiency
Mechanism: Loss-of-function mutations reduce progranulin levels
Phenotype: FTD (behavioral variant, progressive aphasia), CBS

Testing considerations:

Includes deletion/duplication analysis (common mutation type)
Serum progranulin可以作为生物标志物
Family history sometimes negative (de novo mutations)

Reporting Standards

Clinical Report Components

A quality WGS report for CBS/PSP should include:

Patient identification: Demographics, ordering physician
Indication for testing: Clinical diagnosis, family history
Methodology: Sequencing platform, coverage, analysis pipeline
Results summary: Pathogenic, likely pathogenic, VUS identified
Variant details: Gene, cDNA change, protein change, classification
Interpretation: Pathogenic significance, supporting evidence
Recommendations: Follow-up testing, family studies, counseling
Limitations: Known technical limitations, residual risk

Variant Reporting Format

Field	Example
Gene	MAPT
Transcript	NM_001123
cDNA change	c.1000C>T
Protein change	p.Pro334Leu
Classification	Pathogenic
Evidence	PS3, PM1, PP3

Secondary Findings

Incidental findings unrelated to the indication should be handled per ACMG recommendations:

Reportable genes: 59 genes associated with actionable conditions
Incidental findings: 1-2% of WGS in adults
Patient preferences: Opt-in/opt-out options
Counselling needs: Pre-test discussion essential

Quality Metrics

Sequencing Quality Standards

Metric	Minimum	Target
Total throughput	≥90 Gb	≥120 Gb
Mean coverage	≥30x	≥40x
Coverage uniformity	≥85%	≥90% at 20x
Q30 bases	≥80%	≥85%
Duplicate rate	<20%	<15%
Mapping rate	≥98%	≥99%

Variant Calling Metrics

Metric	Acceptable	Optimal
Ti/Tv ratio (exome)	2.5-3.5	3.0-3.3
Ti/Tv ratio (genome)	1.8-2.2	2.0-2.1
Heterozygous/homozygous ratio	2.5-4.0	3.0-3.5
Transition percentage	58-62%	59-61%

Turnaround Time Considerations

Laboratory Processing Timeline

Phase	Duration	Notes
Sample receipt	Day 1	QC check, DNA extraction if needed
Library preparation	Day 2-5	Quality control, quantification
Sequencing	Day 6-10	Depends on sequencer capacity
Bioinformatics	Day 11-14	Alignment, variant calling
Interpretation	Day 15-21	Clinical review, report generation
Report review	Day 22-28	Quality assurance, physician sign-off

Expedited Options

For urgent clinical scenarios:

Rapid WGS: 2-3 week turnaround (limited availability)
Exome-first approach: Faster for known gene suspicion
Prioritization: Certain variants fast-tracked for interpretation

Insurance Considerations

Coverage Determination

Payer	Typical Coverage	Requirements
Medicare	Variable	Medical necessity documentation
Medicaid	State-dependent	Prior authorization common
Commercial	Often covered	Pre-authorization required
Self-pay	Full cost	Payment plans available

Appeals Process

If coverage is denied:

Letter of medical necessity: Emphasize diagnostic value
Literature support: Cite diagnostic yield studies
Peer-to-peer review: Direct clinician discussion
State coverage mandates: Check applicable laws
Patient assistance programs: Lab-based financial support

Future Technologies

Long-Read Sequencing Advances

Oxford Nanopore and PacBio HiFi are revolutionizing WGS:

Read lengths: 10-50 kb typical (Nanopore), 10-20 kb (HiFi)
Structural variants: Dramatically improved detection
Repeat expansions: Direct measurement of repeat counts
Methylation: Native 5mC detection
Cost trajectory: Declining rapidly, approaching short-read

Emerging Applications

Metagenomic sequencing: Infectious triggers
RNA-seq integration: Functional validation
Single-cell WGS: Rare variant detection
Longitudinal analysis: Clonal evolution

Implementation Readiness

Technology	Clinical Readiness	Notes
Short-read WGS	Mature	Standard of care
Long-read WGS	Early adoption	Expert centers
Hybrid approaches	Research	Emerging
AI interpretation	Limited	Active development

Conclusion

Technical Advances

Long-read WGS: Improved structural variant detection
RNA sequencing: Functional validation of variants
Single-cell analysis: Cellular heterogeneity
Artificial intelligence: Enhanced variant interpretation

Clinical Evolution

Integration with electronic health records: Automated alerts
Rapid WGS: Faster turnaround for acute care
Population screening: Broader implementation
Precision medicine: Genotype-guided treatment

Conclusion

Whole genome sequencing represents a powerful diagnostic tool for corticobasal syndrome and progressive supranuclear palsy, providing diagnostic yield of 15-30% even in apparently sporadic cases. While targeted panels remain appropriate for initial testing, WGS offers comprehensive coverage of all variant types including non-coding changes, structural variants, and rare genetic causes.

The clinical implementation of WGS requires careful pre-test counseling, appropriate laboratory selection, and multidisciplinary interpretation. When pathogenic variants are identified, cascade testing provides valuable information for at-risk family members. As sequencing costs decline and interpretation improves, WGS is likely to become first-line testing for atypical parkinsonian syndromes.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Whole Genome Sequencing for CBS/PSP discovered through SciDEX knowledge graph analysis:

graph TD
    ALZHEIMER["ALZHEIMER"] -->|"associated with"| PSP["PSP"]
    MOBP["MOBP"] -->|"regulates"| PSP["PSP"]
    TAU["TAU"] -->|"activates"| PSP["PSP"]
    SNCA["SNCA"] -->|"therapeutic target"| PSP["PSP"]
    TAU["TAU"] -->|"associated with"| PSP["PSP"]
    CDKN2A["CDKN2A"] -->|"associated with"| PSP["PSP"]
    UBIQUITIN["UBIQUITIN"] -->|"expressed in"| PSP["PSP"]
    TAU["TAU"] -->|"expressed in"| PSP["PSP"]
    P62["P62"] -->|"expressed in"| PSP["PSP"]
    AKT["AKT"] -->|"activates"| PSP["PSP"]
    PI3K["PI3K"] -->|"activates"| PSP["PSP"]
    MAPT["MAPT"] -->|"activates"| PSP["PSP"]
    NLGN1["NLGN1"] -.->|"inhibits"| PSP["PSP"]
    TUBULIN["TUBULIN"] -.->|"inhibits"| PSP["PSP"]
    PI3K["PI3K"] -->|"treats"| PSP["PSP"]
    style ALZHEIMER fill:#ce93d8,stroke:#333,color:#000
    style PSP fill:#ce93d8,stroke:#333,color:#000
    style MOBP fill:#ce93d8,stroke:#333,color:#000
    style TAU fill:#ce93d8,stroke:#333,color:#000
    style SNCA fill:#ce93d8,stroke:#333,color:#000
    style CDKN2A fill:#ce93d8,stroke:#333,color:#000
    style UBIQUITIN fill:#ce93d8,stroke:#333,color:#000
    style P62 fill:#ce93d8,stroke:#333,color:#000
    style AKT fill:#ce93d8,stroke:#333,color:#000
    style PI3K fill:#ce93d8,stroke:#333,color:#000
    style MAPT fill:#ce93d8,stroke:#333,color:#000
    style NLGN1 fill:#ce93d8,stroke:#333,color:#000
    style TUBULIN fill:#ce93d8,stroke:#333,color:#000

Whole Genome Sequencing for CBS/PSP

3.4 Whole Genome Sequencing (WGS)

Recommended Strategy

Short-Read WGS (Illumina)

Long-Read WGS (PacBio/Nanopore)

Recommendation for This Patient

Insurance Coverage

Patient Action Items

Genetic Architecture of CBS and PSP

Known Genetic Causes

Autosomal Dominant Genes

Autosomal Recessive Genes

Variant Spectrum

Genetic Risk Factors

Technical Considerations for WGS

Sequencing Parameters

Bioinformatics Pipeline

Coverage Considerations

Interpretation Challenges

Variant Classification

VUS Management

Technical Limitations

Clinical Utility of WGS

Diagnostic Yield

Comparison with Targeted Panels

Family Testing Implications

Cascade Testing

Ethical Considerations

Pre-Test Counseling

Research Applications

Gene Discovery

Biomarker Development

Therapeutic Targets

Quality Assurance

Laboratory Standards

Validation Requirements

Cost-Effectiveness

Healthcare Economics

Value Components

Implementation Recommendations

Clinical Workflow

Sample Requirements

Specific Gene Considerations

MAPT (Microtubule-Associated Protein Tau)

C9orf72 Hexanucleotide Repeat Expansion

GRN (Progranulin)

Reporting Standards

Clinical Report Components

Variant Reporting Format

Secondary Findings

Quality Metrics

Sequencing Quality Standards

Variant Calling Metrics

Turnaround Time Considerations

Laboratory Processing Timeline

Expedited Options

Insurance Considerations

Coverage Determination

Appeals Process

Future Technologies

Long-Read Sequencing Advances

Emerging Applications

Implementation Readiness

Conclusion

Technical Advances

Clinical Evolution

Conclusion

See Also

References

Pathway Diagram